hotspot -WSS

hotspot

author：explore 2025-10-01 13:59:23 - browse：71

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Steward Health Care files for bankruptcy

Wikipedia

leisure time

hotspot

WSS

How to improve immunocompromised access to mAb treatments

2 officers injured in shooting in Orlando, police say

H5N1 communication has been strictly for the birds

Use wet bulb globe temperature, not heat index, to protect workers

Sanofi strikes deal with Novavax, boosting the vaccine maker

H.R. 3 is the wrong path to lower drug costs

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

entertainment

Trump demands the U.S. pay no more for drugs than other countries … again

How I helped Pfizer think through the ethics of Viagra

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

H5N1 communication has been strictly for the birds

Activists slam private health insurers over coverage restrictions

Medicare slashes safety net hospital payments by nearly $1 billion

Alkermes shareholders re

Alnylam reports growth in sales of rare disease treatments

Apple is now the first public company to be valued at $3 trillion

Readout LOUD podcast: What to know about H5N1 bird flu

focus

A controversial new treatment promises to make little people taller

Late stage cancers on the rise after pandemic delayed screenings

Telehealth startups turn to complex chronic diseases

Steward Health Care files for bankruptcy

H5N1 bird flu: what we're starting to learn about infection in cows

Google says AlphaFold 3 can map a vast universe of biomolecules

Wikipedia

leisure time

hotspot

knowledge